CD8A and melanoma: Compared to PTT alone and vaccine-based immunotherapy, OVA-ICG nanovaccine therapy significantly increased the number of CD8+ T cells in tumors, which was found to not only significantly inhibit the growth of melanoma cells but also triggered an immune memory effect that almost completely eliminated re-emerging melanoma.